Public Employees Retirement Association of Colorado Decreases Stock Holdings in Insulet Co. (NASDAQ:PODD)

Public Employees Retirement Association of Colorado reduced its holdings in shares of Insulet Co. (NASDAQ:PODD) by 3.1% during the second quarter, HoldingsChannel.com reports. The fund owned 7,183 shares of the medical instruments supplier’s stock after selling 230 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Insulet were worth $1,450,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Dimensional Fund Advisors LP boosted its stake in Insulet by 0.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 124,280 shares of the medical instruments supplier’s stock valued at $26,968,000 after acquiring an additional 834 shares during the last quarter. Janney Montgomery Scott LLC lifted its stake in Insulet by 15.1% in the fourth quarter. Janney Montgomery Scott LLC now owns 7,487 shares of the medical instruments supplier’s stock valued at $1,624,000 after purchasing an additional 982 shares during the last quarter. UBS Group AG lifted its stake in Insulet by 0.9% in the fourth quarter. UBS Group AG now owns 61,404 shares of the medical instruments supplier’s stock valued at $13,323,000 after purchasing an additional 535 shares during the last quarter. Corient Private Wealth LLC grew its holdings in Insulet by 72.7% during the fourth quarter. Corient Private Wealth LLC now owns 8,053 shares of the medical instruments supplier’s stock valued at $1,747,000 after purchasing an additional 3,389 shares during the period. Finally, Assetmark Inc. increased its position in Insulet by 10.0% in the fourth quarter. Assetmark Inc. now owns 4,711 shares of the medical instruments supplier’s stock worth $1,022,000 after buying an additional 427 shares during the last quarter.

Analysts Set New Price Targets

A number of brokerages have recently commented on PODD. Barclays upped their price target on Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. OTR Global reaffirmed a “mixed” rating on shares of Insulet in a report on Monday, June 10th. BTIG Research reduced their target price on shares of Insulet from $270.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, August 9th. UBS Group boosted their price target on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Finally, Piper Sandler raised their price objective on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $229.21.

Insulet Stock Up 0.0 %

PODD opened at $239.01 on Wednesday. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71. Insulet Co. has a one year low of $125.82 and a one year high of $243.98. The firm has a market capitalization of $16.74 billion, a P/E ratio of 72.43, a price-to-earnings-growth ratio of 4.38 and a beta of 1.21. The company has a fifty day moving average price of $204.43 and a 200-day moving average price of $189.34.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). The business had revenue of $488.50 million during the quarter, compared to the consensus estimate of $488.00 million. Insulet had a return on equity of 30.73% and a net margin of 21.11%. Insulet’s revenue was up 23.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.38 earnings per share. Equities research analysts expect that Insulet Co. will post 3.04 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.